1708 – Hepatitis Delta Virus (HDV) RNA PCR testing to determine eligibility for PBS-subsidised bulevirtide (HEPCLUDEX) for treatment of HDV

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation Closed
  • Pre-MSAC consultation Closed
  • Outcome Not supported

Application details

Reason for application

New MBS item.

Service or technology in this application

Polymerase chain reaction (PCR) testing is a method used to rapidly make copies of a small DNA sample and amplify it to a large enough amount to study in detail. PCR tests work by taking a sample of blood, saliva, mucus, or tissue. An enzyme called polymerase is added to the sample. This causes the sample to produce copies, which is repeated multiple times. If a virus or pathogen is present, it will be indicated on the testing machine.

Type: Investigative technology

Medical condition this application addresses

Hepatitis delta virus (HDV) is a rare blood-borne virus that occurs in people infected with the hepatitis B virus. The liver disease associated with HDV runs a more progressive course than chronic hepatitis B, and may lead to cirrhosis within 2 years in 10–15% of patients.

Application documents

Consultation survey and deadlines

  • PASC consultation: Closed
  • MSAC consultation: Closed Friday 16 February 2024

Meetings to consider this application

  • PASC meeting: 13–14 April 2022
  • ESC meeting: 15–16 February 2024
  • MSAC meeting: 4–5 April 2024